Jonathon Miller

Research Summary

Study of the regulation of the platelet receptor for von Willebrand factor (glycoprotein Ib/IX/V complex), with long-term goal the development of anti-thrombotic agents based upon insights gained from study of the pathophysiology of platelet-type von Willebrand disease and the Bernard-Soulier disease syndromes; molecular characterization of autoantibody development against the glycoprotein Ib/IX/V complex in ITP.

Selected Papers

Chitale N, Miller JL. (2001). Complete inhibition of shear-induced platelet aggregation (SIPA) by HIb-2, a human anti-human platelet GPIb ScFv. Blood.

Miller JL, Awasthi A, Lyle VA, Blystone SD, Gavalchin J. (2001). Detection of human anti-platelet antibodies using a fluorescence resonance energy transfer approach with heterologous cells. Thromb Haem Suppl.

Mathur SC, Vajpayee N, Narsipur SS, Miller JL. (2001). Changes in platelet function following hemodialysis in patients with end-stage renal disease. Thromb Haem Suppl.

Doggett TA, Girdhar G, Lawshe A, Miller JL, Laurenzi IJ, Diamond SL, Diacovo TG. (2003). Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val. Blood. 120:152-160.